Autologous peripheral blood progenitor cell (PBPC) transplant recipients frequently receive multiple antibiotics for neutropenic fever in addition to high-dose chemotherapy. Although there are many possible causes for diarrhea in this population, empiric therapy for possible C. difficile colitis is common in some centers. Diarrhea is a major cause of morbidity during high-dose chemotherapy followed by autologous peripheral blood progenitor cell (PBPC) transplant. Diarrhea in this setting is often persistent, profuse, and incompletely responsive to symptomatic management. It is generally attributed to the gastrointestinal mucosal effects of high-dose chemotherapy,
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Clostridium difficile colitis is a recognized cause of diarrhea in hospitalized patients and may be spread nosocomially. [1] [2] [3] [4] [5] [6] Outbreaks of C. difficile on particular hospital units have been reported. 4 C. difficile has been implicated in 15-25% of cases of antibiotic-associated diarrhea. 1 Occasionally, sequelae of C. difficile may include colonic dilatation, hemorrhage, perforation, or the need for urgent surgical intervention to prevent these complications. 1, 3, 5 Such complications may be seen more frequently in patients with severe underlying illnesses. 7 For this reason, clinicians caring for bone marrow transplant recipients may be particularly anxious to diagnose and treat any colitis due to C. difficile early and aggressively.
In an era where the rise of vancomycin-resistant enterococci (VRE) has led to a re-evaluation of the indications for vancomycin use, [8] [9] [10] the use of empiric oral vancomycin for C. difficile therapy has come under scrutiny. Relatively few studies have addressed the issue of the frequency of diarrhea and C. difficile colitis in PBPC recipients, 11, 12 although several studies have been performed in allogeneic bone marrow recipients. [13] [14] [15] [16] The objectives of the current study were to compare the frequency of diarrhea with the frequency of a positive C. difficile toxin assay, in a representative group of patients undergoing PBPC transplant.
Methods
Eighty patients undergoing autologous PBPC were enrolled in a prospective randomized trial of two empiric regimens for febrile neutropenia: vancomycin, ceftazidime, and tobramycin at standard doses vs single-daily dose vancomycin and tobramycin with oral ciprofloxacin. 17 Data were collected on the occurrence of diarrhea, as recorded in clinician daily chart notes, and nursing notes which included volume of liquid stools and number of stools. All microbiologic tests ordered during the study period were recorded, including C. difficile toxin assays, which were ordered according to clinician preference. Data on stool consistency were not recorded. However, the laboratory at this center only performs C. difficile toxin assays on stool which is not formed; thus all samples processed by the laboratory represented non-formed stool.
C. difficile toxin assays were performed using an enzyme immunoassay for the detection of C. difficile toxin A (Becton Dickinson Toxin CD Test/Enzyme Immunoassay; Becton Dickinson, Sparks, MD, USA). The reported sensitivity is 76%, specificity is 99%, positive predictive value 94%, and negative predictive value 96%, similar to other current toxin A detection assays. In this laboratory, testing for C. difficile toxin is performed either once or twice daily, depending on the volume of samples received. The time to processing is less than 24 h and frequently less than 6 h; if greater than 6 h, the sample is refrigerated.
Results
Sixty-one of 80 patients (76.3%) developed diarrhea during PBPC transplant. Of these, 3/61 patients (4.9%) had a positive C. difficile toxin assay. A total of 122 C. difficile toxin assays were performed for an average of two assays per patient with diarrhea (range 0-10). Fifty-six of 61 patients with diarrhea (92%) had at least one C. difficile toxin assay performed. For each positive stool assay, 41 stool samples were analyzed.
Therapy for diagnosed or presumed C. difficile colitis was administered in 25 of 61 patients with diarrhea (41%). Therapy was administered according to clinician preference and was not specified in the study protocol. This included 20 courses of oral metronidazole (two for positive assay, 18 empiric) and 10 courses of oral vancomycin (two for positive assay, eight empiric). Five patients received sequential courses of metronidazole and oral vancomycin (one patient with a positive C. difficile assay and four patients with negative assays).
The cost of a course of oral vancomycin during that time period was approximately 100 times that of a course of oral metronidazole. The cost of therapy prescribed for suspected or proven C. difficile in this group of patients was $578 per positive assay. The cost of C. difficile assays performed was $409.5 per positive assay.
Discussion
C. difficile colitis is a significant clinical problem in the hospitalized patient with concurrent medical problems. One commonly used diagnostic assay is the C. difficile cytotoxin enzyme immunoassay. 18 This test is rapid and relatively easy to perform, but may have a greater than 10% false negative rate on initial testing. 18 Concern over C. difficile and its possible consequences may lead clinicians to institute empiric therapy despite a negative toxin assay. Sigmoidoscopy to detect the presence of characteristic pseudomembranes, although useful in some groups of patients, is potentially hazardous in the neutropenic patient. Therefore, the decision of whether or not to treat for possible C. difficile in this patient population is frequently a matter of clinical judgment. However, until recently, 11 there have been few data to guide this decision in terms of the prevalence of C. difficile in PBPC transplant recipients with diarrhea.
Another compelling consideration is the widespread emergence of vancomycin-resistant Gram-positive bacteria, especially enterococci (VRE). This has been clearly linked to vancomycin use. 8, 10 In particular, oral vancomycin, which is limited in distribution to the gastrointestinal tract, may predispose to colonization with VRE by inhibiting the growth of sensitive microorganisms. 8 The Centers for Disease Control has issued a set of guidelines designed to limit vancomycin use to specific indications 8 with the goal of reducing the spread of vancomycin resistance. Vancomycin restriction policies are being implemented at many centers in accordance with these guidelines. 9 Although metronidazole is the preferred form of initial therapy for C. difficile, both with respect to its cost and resistance issues, it has been suggested that large-scale metronidazole use may also contribute to the emergence of VRE. 19 It would therefore be desirable to balance the risks of 'assay-negative' C. difficile in any particular patient against the risks of empiric antibiotic therapy in the population as a whole.
Few studies have addressed the frequency of C. difficile in PBPC patients. A recent retrospective evaluation of autologous PBPC recipients found C. difficile in 14 of 200 patients (7%); however, the overall incidence of diarrhea in this patient group was not reported. 11 A prospective study of 296 patients undergoing allogeneic marrow transplantation revealed C. difficile in only six of 126 patients (4.8%) with diarrhea. 13 Other studies in allogeneic marrow recipients have demonstrated C. difficile in 12/78 patients (15.4%) 14 and 14% of 24 diarrhea episodes. 15 Bacterial pathogens including C. difficile were identified in 9/44 episodes of enterocolitis in 143 bone marrow transplant recipients. 16 In the current study, three-quarters of patients developed diarrhea during transplant but only 4.9% had a positive C. difficile toxin assay. Even taking into account the possibility of underdetection due to the false-negative rate of the assay, this is an extremely low rate of identification of C. difficile compared to the incidence of diarrhea as a whole. By contrast, empiric therapy for possible C. difficile was common (41% of patients with diarrhea).
Recent work has demonstrated an overall reduction of infectious complications in autologous bone marrow transplant and PBPC transplant recipients in the current era of a shorter duration of neutropenia with the use of hematopoietic growth factors. 20 In a study of infectious complications in 219 recipients of autologous BMT, 1/219 (0.5%) developed C. difficile colitis. 20 However, as this study demonstrates, diarrhea remains a prominent part of early posttransplant clinical symptomatology and evokes concern on the part of clinicians. This study suggests that diarrhea in this population is frequent, but only infrequently due to C. difficile. Other possibilities include gastrointestinal mucosal injury, non-C. difficile antibiotic-associated diarrhea, other medications, or other pathogens such as enteric viruses. 13 If empiric therapy for C. difficile is administered, antibiotic resistance and cost considerations favor metronidazole as initial therapy. However, tolerance of metronidazole may be poor in PBPC transplant recipients due to nausea after chemotherapy. Thus, intended empiric courses of metronidazole may in practice be converted to empiric oral vancomycin because of gastrointestinal intolerance of metronidazole. Clinicians should be aware that, in initiating empiric therapy, they may be increasing the use of oral vancomycin by this mechanism.
In conclusion, the decision to administer empiric therapy for C. difficile to PBPC transplant recipients in a non-outbreak setting should take into account the risks, benefits, and costs of such therapy. Development of more sensitive C. difficile assays may help to decrease courses of empiric therapy. However, regardless of the assay performed, it is clear that many other etiologies for diarrhea appear to be far more common in this population, unless a nosocomial outbreak is taking place.
